Search results for "double-blind"

showing 10 items of 662 documents

Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men

2004

The aim of the present study was to evaluate whether olive oils high in phenolic compounds influence the oxidative/antioxidative status in humans. Healthy men (n = 12) participated in a double-blind, randomized, crossover study in which 3 olive oils with low (LPC), moderate (MPC), and high (HPC) phenolic content were given as raw doses (25 mL/d) for 4 consecutive days preceded by 10-d washout periods. Volunteers followed a strict very low-antioxidant diet the 3 d before and during the intervention periods. Short-term consumption of olive oils decreased plasma oxidized LDL (oxLDL), 8-oxo-dG in mitochondrial DNA and urine, malondialdehyde in urine (P < 0.05 for linear trend), and increased HD…

AdultMaleTime FactorsMedicine (miscellaneous)Urinemedicine.disease_causeDNA MitochondrialAntioxidantschemistry.chemical_compoundDouble-Blind MethodPhenolsMalondialdehydemedicineHumansPlant OilsPhenolsFood scienceOlive OilGlutathione PeroxidaseNutrition and DieteticsCross-Over StudiesDose-Response Relationship DrugCholesterolCholesterol HDLDeoxyguanosineMalondialdehydePostprandial PeriodDietLipoproteins LDLDose–response relationshipVegetable oilPostprandialchemistryBiochemistry8-Hydroxy-2'-DeoxyguanosineOxidation-ReductionOxidative stress
researchProduct

Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers.

1998

Paroxetine is a selective and potent serotonin reuptake inhibitor with reported antidepressant properties. Since changes in the regular sleeping pattern were described as side effects under treatment with paroxetine, the impact of the drug on the sleep architecture is of major interest. The present study addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover-design. Conventional sleep EEG parameters and additionally computed spectral power analysis based on FFT of 20-s time epochs in the delta, theta, alpha, beta and gamma frequency range for different sleep stages after 4 weeks of tr…

AdultMaleTime FactorsSerotonin reuptake inhibitorSleep REMNon-rapid eye movement sleepDouble-Blind MethodReference ValuesmedicineHumansPharmacology (medical)Biological PsychiatrySlow-wave sleepPharmacologySleep StagesAnalysis of VarianceCross-Over StudiesElectroencephalographySleep in non-human animalsParoxetineCircadian RhythmPsychiatry and Mental healthParoxetineNeurologyAnesthesiaAntidepressantAntidepressive Agents Second-GenerationNeurology (clinical)Sleep onset latencyPsychologySleepSelective Serotonin Reuptake Inhibitorsmedicine.drugEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Contralateral hand anesthesia transiently improves poststroke sensory deficits.

2005

Objective To test a possible strategy to alleviate somatosensory deficits after stroke. Methods Here, we applied ischemic nerve block to the intact hand of patients with chronic stroke, which in healthy subjects elicits improvements in sensibility of the other hand. Results We found that sensibility in the affected hand improved with intact hand anesthesia, but not with intact foot anesthesia or no anesthesia. Interpretation We conclude that reduction of sensory input from the intact hand leads to site-specific improvements in tactile discriminative skills in the affected hand after the period of anesthesia, a potentially relevant finding in designing neurorehabilitative interventions. Ann …

AdultMaleTime Factorsmedicine.medical_treatmentSensory systemSomatosensory systemFunctional LateralityDouble-Blind MethodReaction TimeMedicineHumansAnesthesiaChronic strokeStrokeAgedAnalysis of VarianceHand Strengthbusiness.industryHealthy subjectsMiddle Agedmedicine.diseaseHandStrokeSensory inputNeurologyAnesthesiaSensory ThresholdsSensation DisordersNerve blockFemaleNeurology (clinical)businessPsychomotor PerformanceAnnals of neurology
researchProduct

Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative.

2006

Contains fulltext : 49580.pdf (Publisher’s version ) (Open Access) BACKGROUND: Regenerative periodontal therapy with an enamel matrix protein derivative (EMD) has been shown to promote regeneration in intrabony periodontal defects. However, in most clinical studies, root surface conditioning with EDTA was performed in conjunction with the application of EMD, and, therefore, it cannot be excluded that the results may also be attributable to the effect of the root conditioning procedure. The purpose of this study was to determine the effect of root conditioning on the healing of intrabony defects treated with EMD. METHODS: Twenty-four patients, each of whom exhibited one deep intrabony defect…

AdultMaleTissue engineering and reconstructive surgery [UMCN 4.3]Bone RegenerationRoot surfaceOral Surgical ProceduresBleeding on probingAlveolar Bone LossDentistryDerivativeDental Enamel ProteinsDouble-Blind MethodmedicineHumansProspective StudiesTooth RootEdetic AcidChelating AgentsEnamel paintbusiness.industryChemistryOpen flap debridementAttachment levelGingival indexvisual_artvisual_art.visual_art_mediumPeriodonticsConditioningFemalePeriodontal Indexmedicine.symptombusiness
researchProduct

Time course of adverse events most commonly associated with topiramate for migraine prevention

2007

The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double-blind, placebo-controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in/=2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double-blind, placebo-controlled, and 26-week trials. The pooled population comprised all randomized patients who reported safety data during the double-blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4-week titration period and a 22-week maintenance period. Incidence, time to onset, and cumulative mean rate of …

AdultMaleTopiramateTime FactorsNauseaMigraine DisordersPopulationFructosePlaceboTimelaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialTopiramatelawmedicineHumansParesthesiaeducationFatigueeducation.field_of_studyDose-Response Relationship Drugbusiness.industryNauseaMiddle Agedmedicine.diseaseAnorexiaDiscontinuationWithholding TreatmentNeurologyTolerabilityMigraineAnesthesiaPatient ComplianceAnticonvulsantsFemaleNeurology (clinical)medicine.symptomCognition Disordersbusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-contro…

2019

Introduction Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with migraine on the basis of mechanistic rationale and pilot clinical data. Methods This multicentre study included a 4-week run-in period, a 12-week double-blind period of randomised treatment with nVNS or sham, and a 24-week open-label period of nVNS. Patients were to administer two 120-second stimulations bilaterally to the neck three times daily (6–8 hours apart). Results Of 477 enrolled patients, 332 comprised the intent-to-treat (ITT) population. Mean reductions in migraine days per month (primary outcome) were 2.26 for nVNS (n = 165; baseline, 7.9 days) and 1.8…

AdultMaleVagus Nerve StimulationMigraine DisordersMigraine prophylaxismedicine.medical_treatmentMedizinlaw.inventionDouble blindvagal activation03 medical and health sciences0302 clinical medicineDouble-Blind MethodEpisodic migraineRandomized controlled triallawHumanspreventive therapyMedicineIn patient030304 developmental biologymigraine prophylaxis0303 health sciencesNeuromodulationbusiness.industryNon invasiveNon-pharmacologic treatmentOriginal ArticlesGeneral MedicineMiddle Agedmedicine.diseaseNeuromodulation (medicine)3. Good healthTreatment OutcomeMigrainenon-pharmacologic treatmentAnesthesiaVagal activationFemaleNeurology (clinical)Preventive therapybusinessRCT030217 neurology & neurosurgeryVagus nerve stimulationCephalalgia
researchProduct

Pentaerythrityl Tetranitrate and Nitroglycerin, but not Isosorbide Mononitrate, Prevent Endothelial Dysfunction Induced by Ischemia and Reperfusion

2007

Background— Short term exposure to nitroglycerin (GTN) has protective properties that are similar to ischemic preconditioning. Whether other organic nitrates such as pentaerithrityl tetranitrate (PETN) and isosorbide mononitrate (ISMN) have similar protective effects has not been explored. Methods and Results— In a randomized, parallel, double blind, controlled trial, 37 healthy young volunteers received no therapy (n=10), transdermal GTN 1.2 mg for 2 hours (n=9), PETN 80 mg (n=9), or ISMN 40 mg (n=9). Twenty-four hours later, endothelium-dependent flow-mediated vasodilation (FMD) was measured before and after local exposure to ischemia and reperfusion (IR). In the no therapy group, IR blu…

AdultMaleVasodilator AgentsIschemiaVasodilationPentaerythritol tetranitrateIsosorbide DinitratePharmacologyNitroglycerinchemistry.chemical_compoundDouble-Blind MethodmedicineIsosorbide mononitrateHumansPentaerythritol TetranitrateEndothelial dysfunctionIschemic PreconditioningChemistrymedicine.diseaseReperfusion InjuryAnesthesiacardiovascular systemIschemic preconditioningEndothelium VascularIsosorbide dinitrateCardiology and Cardiovascular MedicineReperfusion injurymedicine.drugArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Application of a capsaicin rinse in the treatment of burning mouth syndrome

2010

Objective: To examine the efficacy of a new topical capsaicin presentation as an oral rinse in improving the symptoms of burning mouth syndrome (BMS). Study design: A prospective, double-blind, cross-over study was made of 30 patients with BMS. There were 7 dropouts; the final study series thus comprised 23 individuals. The patients were randomized to two groups: (A) capsaicin rinse (0.02%) or (B) placebo rinse, administered during one week. After a one-week washout period, the patients were then assigned to the opposite group. Burning discomfort was scored using a visual analog scale (VAS): in the morning before starting the treatment, in the afternoon on the first day of treatment, and at…

AdultMaleVisual analogue scaleAdministration TopicalMouthwashesBurning Mouth SyndromePlaceboOdontologialaw.inventionchemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawMedicineHumansProspective StudiesProspective cohort studyGeneral DentistryMorningAgedAged 80 and overCross-Over StudiesOral Medicine and Pathologybusiness.industryBurning mouth syndromeMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Crossover studyOtorhinolaryngologychemistryCapsaicinAnesthesiaUNESCO::CIENCIAS MÉDICASEstomatologiaSensory System AgentsSurgeryFemaleResearch-Articlemedicine.symptomCapsaicinbusinessCremades
researchProduct

Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain

2007

What is already known about this subject • Despite encouraging effects of N-methyl-D-aspartate (NMDA) receptor antagonists in reducing neuropathic pain of different aetiologies, the clinical use of these agents has been limited by their mainly psychotropic side-effects. • In a recent study in healthy volunteers, CNS 5161, a novel noncompetetive NMDA receptor antagonist, was well tolerated up to a dosage of 2000 µg without psychotropic side-effects. • This is the first study to evaluate the maximal tolerated dosage of CNS 5161 and to gain experience about the analgesic effect of CNS 5161 in patients with different pain syndromes. What this study adds • In patients with neuropathic pain CNS 5…

AdultMaleVisual analogue scaleAnalgesicPlaceboGuanidinesReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundDrug SafetyDouble-Blind MethodMedicineHumansPharmacology (medical)Glutamate receptor antagonistSulfhydryl CompoundsAdverse effectAgedPain MeasurementPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryTherapeutic effectMiddle AgedBlood pressurechemistryAnesthesiaNeuropathic painNeuralgiaFemalebusiness
researchProduct

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

2006

Purpose: To evaluate the safety and efficacy of recombinant human iduronate-2-sulfatase (idursulfase) in the treatment of mucopolysaccharidosis II. Methods: Ninety-six mucopolysaccharidosis II patients between 5 and 31 years of age were enrolled in a double-blind, placebo-controlled trial. Patients were randomized to placebo infusions, weekly idursulfase (0.5 mg/kg) infusions or every-other-week infusions of idursulfase (0.5 mg/kg). Efficacy was evaluated using a composite endpoint consisting of distance walked in 6 minutes and the percentage of predicted forced vital capacity based on the sum of the ranks of change from baseline. Results: Patients in the weekly and every-other-week idursul…

AdultMaleVital capacitymedicine.medical_specialtyAdolescentIdursulfaseVital CapacityIduronate SulfatasePlacebolaw.inventionchemistry.chemical_compoundDouble-Blind MethodRandomized controlled trialElosulfase alfalawInternal medicinemedicineHumansMucopolysaccharidosis type IIChildGenetics (clinical)GlycoproteinsMucopolysaccharidosis IIbusiness.industryHunter syndromeDrug ToleranceEnzyme replacement therapymedicine.diseaseRecombinant ProteinsSurgerychemistryChild PreschoolSafetybusinessmedicine.drugGenetics in Medicine
researchProduct